Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 6/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8069279 | 0.92 | HPGD (0.44) | OPRD1OPRM1 | |
| SCHEMBL4576368 | 0.90 | OPRD1 (0.41) | OPRD1OPRM1 | |
| SCHEMBL4576731 | 0.88 | OPRD1 (0.46) | OPRD1OPRM1CYP1A2CYP3A4 | |
| SCHEMBL2751386 | 0.84 | SRD5A2 (0.39) | — | |
| SCHEMBL1989199 | 0.83 | OPRD1 (0.63) | OPRD1OPRM1CYP1A2CYP3A4 | |
| SCHEMBL8083626 | 0.83 | HPGD (0.43) | OPRD1OPRM1 | |
| SCHEMBL6935563 | 0.82 | CNR2 (0.40) | OPRD1OPRM1 | |
| SCHEMBL6936151 | 0.82 | HPGD (0.55) | OPRD1OPRM1 | |
| SCHEMBL6271969 | 0.81 | OPRD1 (0.75) | OPRD1OPRM1 | |
| SCHEMBL6102674 | 0.80 | LMNA (0.50) | OPRD1OPRM1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160200689-A1 | DELTA OPIOID RECEPTOR AGONIST COMPOUNDS | VERSI GROUP LLC (US) | 2016-07-14 | — | — | US | disclosed |
| US-9296707-B2 | Delta opioid receptor agonist compounds | VERSI GROUP, LLC (US) | 2016-03-29 | — | — | US | disclosed |
| US-8865721-B2 | Delta opioid receptor agonist compounds | VERSI GROUP, LLC (US) | 2014-10-21 | — | — | US | disclosed |
| US-20140031367-A1 | DELTA OPIOID RECEPTOR AGONIST COMPOUNDS | VERSI GROUP, LLC (US) | 2014-01-30 | — | — | US | disclosed |
| US-8575169-B2 | Method of treating sexual dysfunctions with delta opioid receptor agonist compounds | VERSI GROUP, LLC (US) | 2013-11-05 | — | — | US | disclosed |
| US-8551998-B2 | Delta opioid receptor agonist compounds | VERSI GROUP, LLC (US) | 2013-10-08 | — | — | US | disclosed |
| US-20130053326-A9 | Method of treating sexual dysfunctions with delta opioid receptor agonist compounds | CHANG KWEN-JEN (US) | 2013-02-28 | — | — | US | disclosed |
| EP-1469850-B1 | METHOD OF TREATING SEXUAL DYSFUNCTIONS WITH DELTA OPIOID RECEPTOR AGONIST COMPOUNDS | VERSI GROUP LLC (US) | 2013-01-02 | — | — | EP | disclosed |
| US-20120220601-A1 | DELTA OPIOID RECEPTOR AGONIST COMPOUNDS | VERSI GROUP, LLC | 2012-08-30 | — | — | US | disclosed |
| US-20080193383-A1 | COMPOSITIONS AND METHODS FOR REDUCING RESPIRATORY DEPRESSION AND ATTENDANT SIDE EFFECTS OF MU OPIOID COMPOUNDS | ENTA HOLDING LLC | 2008-08-14 | — | — | US | disclosed |
| EP-0938317-A4 | COMPOSITIONS AND METHODS FOR REDUCING RESPIRATORY DEPRESSION | DELTA PHARMACEUTICALS INC (US) | 2000-08-23 | — | — | EP | disclosed |
| EP-1003373-A1 | COMPOSITIONS AND METHODS FOR REDUCING RESPIRATORY DEPRESSION AND ATTENDANT SIDE EFFECTS OF MU OPIOID COMPOUNDS | DELTA PHARMACEUTICALS, INC. (US) | 2000-05-31 | — | — | EP | disclosed |
| US-5985880-A | REDUCING, TREATING OR PREVENTING DRUG-MEDIATED RESPIRATORY DEPRESSION IN AN ANIMAL BY ADMINISTERING A .DELTA. RECEPTOR AGONIST COMPOUND | DELTA PHARMACEUTICALS (US) | 1999-11-16 | — | — | US | disclosed |
| EP-0938317-A1 | COMPOSITIONS AND METHODS FOR REDUCING RESPIRATORY DEPRESSION | DELTA PHARMACEUTICALS, INC. (US) | 1999-09-01 | — | — | EP | disclosed |
| WO-1999001033-A1 | COMPOSITIONS AND METHODS FOR REDUCING RESPIRATORY DEPRESSION AND ATTENDANT SIDE EFFECTS OF MU OPIOID COMPOUNDS | DELTA PHARMACEUTICALS, INC. (US) | 1999-01-14 | — | — | WO | disclosed |
| US-5854249-A | Opioid diarylmethylpiperazines and piperidines | DELTA PHARMACEUTICALS, INC. (US) | 1998-12-29 | — | — | US | disclosed |
| US-5807858-A | DIARYLMETHYLPIPERAZINE AND PIPERIDINE COMPOUNDS; SIDE EFFECTREDUCTION OF ANALGESICS | DELTA PHARMACEUTICAL, INC. (US) | 1998-09-15 | — | — | US | disclosed |
| WO-1997046240-A1 | COMPOSITIONS AND METHODS FOR REDUCING RESPIRATORY DEPRESSION | DELTA PHARMACEUTICALS, INC. (US) | 1997-12-11 | — | — | WO | disclosed |
| US-5658908-A | RECEPTOR BINDING SPECIES FOR MEDIATING ANALGESIA, COMBATTING DRUG ADDICTION, DRUG OVERDOSE | DELTA PHARMACEUTICALS, INC. (US) | 1997-08-19 | — | — | US | disclosed |
| WO-1993015062-A1 | OPIOID DIARYLMETHYLPIPERAZINES AND PIPERIDINES | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160200689-A1 | DELTA OPIOID RECEPTOR AGONIST COMPOUNDS | OPRD1, OPRM1, OPRK1 | OPRD1 1/4885OPRM1 2/4885CYP1A2 760/4885 |
| US-20080193383-A1 | COMPOSITIONS AND METHODS FOR REDUCING RESPIRATORY DEPRESSION AND ATTENDANT SIDE EFFECTS OF MU OPIOID COMPOUNDS | OPRD1, OPRM1, OPRK1 | OPRD1 1/4885OPRM1 2/4885CYP1A2 751/4885 |
| US-20140031367-A1 | DELTA OPIOID RECEPTOR AGONIST COMPOUNDS | OPRD1, OPRM1, OPRK1 | OPRD1 1/4885OPRM1 2/4885CYP1A2 760/4885 |
| US-20120220601-A1 | DELTA OPIOID RECEPTOR AGONIST COMPOUNDS | OPRD1, OPRM1, OPRK1 | OPRD1 1/4885OPRM1 2/4885CYP1A2 760/4885 |
| US-20130053326-A9 | Method of treating sexual dysfunctions with delta opioid receptor agonist compounds | OPRD1, OPRK1, OPRM1 | OPRD1 1/4885OPRM1 3/4885CYP1A2 656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.